BidaskClub lowered shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) from a buy rating to a hold rating in a research note published on Monday, July 24th.
Several other research firms have also commented on IRWD. Zacks Investment Research upgraded Ironwood Pharmaceuticals from a strong sell rating to a hold rating in a research report on Monday, July 17th. Mizuho boosted their target price on Ironwood Pharmaceuticals from $21.00 to $22.00 and gave the company a buy rating in a research report on Tuesday, July 4th. ValuEngine upgraded Ironwood Pharmaceuticals from a sell rating to a hold rating in a research report on Friday, June 2nd. Wedbush restated a neutral rating and set a $13.00 target price on shares of Ironwood Pharmaceuticals in a research report on Friday, June 16th. Finally, Wells Fargo & Company set a $19.00 target price on Ironwood Pharmaceuticals and gave the company a buy rating in a research report on Saturday, July 22nd. Two research analysts have rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus target price of $18.50.
Ironwood Pharmaceuticals (NASDAQ IRWD) traded down 0.80% during trading on Monday, hitting $14.87. The stock had a trading volume of 1,162,630 shares. Ironwood Pharmaceuticals has a 52-week low of $12.48 and a 52-week high of $19.94. The firm’s market cap is $2.22 billion. The company has a 50-day moving average of $17.75 and a 200 day moving average of $17.13.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.28) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by $0.05. The company had revenue of $65.10 million during the quarter, compared to analysts’ expectations of $70 million. Ironwood Pharmaceuticals had a negative return on equity of 1,028.09% and a negative net margin of 67.96%. The company’s revenue was up 19.7% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.16) EPS. On average, equities research analysts predict that Ironwood Pharmaceuticals will post ($1.10) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “BidaskClub Lowers Ironwood Pharmaceuticals, Inc. (IRWD) to Hold” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://stocknewstimes.com/2017/08/12/bidaskclub-downgrades-ironwood-pharmaceuticals-inc-irwd-to-hold-updated-updated.html.
In other Ironwood Pharmaceuticals news, insider Halley E. Gilbert sold 35,000 shares of the company’s stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $19.75, for a total value of $691,250.00. Following the sale, the insider now directly owns 35,000 shares of the company’s stock, valued at $691,250. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Thomas A. Mccourt sold 30,000 shares of the company’s stock in a transaction on Monday, May 15th. The shares were sold at an average price of $18.20, for a total transaction of $546,000.00. Following the completion of the sale, the insider now directly owns 30,000 shares in the company, valued at $546,000. The disclosure for this sale can be found here. 7.63% of the stock is owned by insiders.
A number of large investors have recently bought and sold shares of IRWD. Strs Ohio raised its stake in Ironwood Pharmaceuticals by 132.1% in the first quarter. Strs Ohio now owns 6,500 shares of the biotechnology company’s stock valued at $110,000 after buying an additional 3,700 shares during the last quarter. Teacher Retirement System of Texas acquired a new stake in Ironwood Pharmaceuticals during the second quarter valued at approximately $192,000. Jane Street Group LLC acquired a new stake in Ironwood Pharmaceuticals during the first quarter valued at approximately $194,000. Karp Capital Management Corp acquired a new stake in Ironwood Pharmaceuticals during the first quarter valued at approximately $201,000. Finally, Raymond James Financial Services Advisors Inc. raised its stake in Ironwood Pharmaceuticals by 8.0% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 12,161 shares of the biotechnology company’s stock valued at $207,000 after buying an additional 898 shares during the last quarter. 98.16% of the stock is currently owned by institutional investors.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.